<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Adults and pediatric patients age 6 years and older: one 150 mg tablet taken orally every 12 hours with fat-containing food. (2, 12.3)<BR>                           Reduce dose in patients with moderate and severe hepatic impairment. (8.6, 12.3)<BR>                           Reduce dose when co-administered with drugs that are moderate or strong CYP3A inhibitors. (7.1, 12.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1	Dosing Information in Adults and Children Ages 6 Years and Older<BR>                     <BR>                        The recommended dose of KALYDECO for both adults and pediatric patients age 6 years and older is one 150 mg tablet taken orally every 12 hours (300 mg total daily dose) with fat-containing food. Examples of appropriate fat-containing food include eggs, butter, peanut butter, cheese pizza, etc. [see <BR>                              Clinical Pharmacology (12.3)<BR>                            and <BR>                              Patient Counseling Information (17.4)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2	Dosage Adjustment for Patients with Hepatic Impairment<BR>                     <BR>                        The dose of KALYDECO should be reduced to 150 mg once daily for patients with moderate hepatic impairment (Child-Pugh Class B). KALYDECO should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C) at a dose of 150 mg once daily or less frequently [see <BR>                              Use in Specific Populations (8.6), <BR>                           <BR>                              Clinical Pharmacology (12.3), and <BR>                              Patient Counseling Information (17.3)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.3	Dosage Adjustment for Patients Taking Drugs that are CYP3A Inhibitors<BR>                     <BR>                        When KALYDECO is being co-administered with strong CYP3A inhibitors (e.g., ketoconazole), the dose should be reduced to 150 mg twice-a-week. The dose of KALYDECO should be reduced to 150 mg once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Food containing grapefruit or Seville oranges should be avoided [see <BR>                              Drug Interactions (7.1), Clinical Pharmacology (12.3), and <BR>                              Patient Counseling Information (17.2)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>